Clinical Trial Update: Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating RVX000222 on time to major adverse cardiovascular events in high-risk type 2 diabetes with coronary artery disease has completed with p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• RVX000222 (apabetalone)

Snippet

Sponsor: Resverlogix Corp | Conditions: Diabetes Mellitus, Type 2, Coronary Artery Disease | Phase 3 | Status: COMPLETED | Results posted: 2021-08-20